B
11.25
-0.06 (-0.53%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Oncology Therapeutics | - | - |
AIStockmoo Score
2.0
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (HC Wainwright & Co., 140.00%) | Buy |
| Median | 25.00 (122.22%) | |
| Low | 23.00 (Oppenheimer, 104.44%) | Buy |
| Average | 25.00 (122.22%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 10.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 17 Sep 2025 | 25.00 (122.22%) | Buy | 10.79 |
| HC Wainwright & Co. | 15 Sep 2025 | 27.00 (140.00%) | Buy | 9.73 |
| Oppenheimer | 04 Sep 2025 | 23.00 (104.44%) | Buy | 10.08 |
| Wedbush | 18 Aug 2025 | 25.00 (122.22%) | Buy | 12.08 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |